Towards new cancer therapies

In 2012, about 8.2 million people died of cancer making the disease a major cause of death worldwide. According to the WHO World Cancer Report 2014, this figure is expected to rise within the next two decades. But new drugs are already in the pipeline. The genetics of fruit flies helps researchers to identify new targets for cancer therapy and to develop more individualised treatments.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Here, one of the leading researchers working on the biochemistry of senescent cells - and their relevance to aging - considers the state of development of senolytic therapies. These are treatments, largely small molecule drugs at this stage, but also including suicide gene therapies, immunotherapies, and more, that are capable of selectively destroying some fraction of the senescent cells present in old tissues. There is tremendous enthusiasm in the scientific and development communities for the potential to create significant degrees of rejuvenation via this approach. The results in mice are far and away more impressive a...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Publication date: 21 May 2019Source: Cell Reports, Volume 27, Issue 8Author(s): Ivan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, Séverine Augier, Aurélie Docquier, Laurent Gros, Rachel Courtois, Cécile Déjou, Diana Jecko, Ondine Becquart, Hélène Rispaud-Blanc, Laurent Gauthier, Benjamin Rossi, Stéphanie Chanteux, Nicolas Gourdin, Beatrice Amigues, Alain Roussel, Armand Bensussan, Jean-François Eliaou, Jérémy BastidSummaryImmune checkpoint inhibitors have revolutionized cancer treatment. However, many cancers are resistant to ICIs, and the targe...
Source: Cell Reports - Category: Cytology Source Type: research
Authors: Lodovichi S, Mercatanti A, Cervelli T, Galli A Abstract Knowledge of interaction network between different proteins can be a useful tool in cancer therapy. To develop new therapeutic treatments, understanding how these proteins contribute to dysregulated cellular pathways is an important task. PARP1 inhibitors are drugs used in cancer therapy, in particular where DNA repair is defective. It is crucial to find new candidate interactors of PARP1 as new therapeutic targets in order to increase efficacy of PARP1 inhibitors and expand their clinical utility. By a yeast-based genome wide screening, we previously...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 20 May 2019Source: Mutation Research/Genetic Toxicology and Environmental MutagenesisAuthor(s): Pavel Vodicka, Sona Vodenkova, Alena Opattova, Ludmila VodickovaAbstractThe last decade witnessed an increase in the use of comet assay for DNA damage monitoring in cancer patients and controls. Apart from case-control studies, reports described the determination of DNA damage prior to (baseline value) and after chemo-/radiotherapy, the treatment resulted in significantly elevated DNA damage. However, studies on DNA damage as a factor reflecting cancer prognosis and therapy prediction are scarc...
Source: Mutation Research Genetic Toxicology and Environmental Mutagenesis - Category: Genetics & Stem Cells Source Type: research
This study aimed to investigate the treatment effects of combining TAE therapy with LY2109761, a transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, on suppressing tumour growth and metastasis. We simulated the changing tumour microenvironment before and after TAE using both in vitro and in vivo models. In vitro, we evaluated the altered migration and invasion properties of HepG2 cells using migration and invasion assays. In addition, western blot analysis was used to investigate molecular mechanisms underlying the biological activities of LY2109761 in HepG2 cells. In vivo, we combined LY2109761 with ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Publication date: Available online 20 May 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Xu Cheng, Dapeng Li, Min Sun, Le He, Yan Zheng, Xin Wang, Rupei TangAbstractChemotherapeutic drugs have a series of limitations in the conventional clinical treatments, mainly including serious adverse effects and multidrug resistance (MDR). Herein, we developed a pH-sensitive polymeric nanoparticle with using poly(ortho ester urethanes) copolymers for co-delivering doxorubicin (DOX) and pyrrolidinedithiocarbamate (PDTC) to settle these problems. Dual-drug-loaded nanoparticles were nano-sized (˜220 nm) with t...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: 15 August 2019Source: Journal of Alloys and Compounds, Volume 797Author(s): D.I. Tishkevich, I.V. Korolkov, A.L. Kozlovskiy, M. Anisovich, D.A. Vinnik, A.E. Ermekova, A.I. Vorobjova, E.E. Shumskaya, T.I. Zubar, S.V. Trukhanov, M.V. Zdorovets, A.V. TrukhanovAbstractMagnetic nanoparticles based on Fe3O4 and their modifications of surface with therapeutic substances are of great interest, especially drug delivery for cancer therapy includes boron-neutron capture therapy. The results of boron-rich compound (carborane borate) attachment to previously aminated by (3-aminopropyl)-trimethoxysilane iron oxide nano...
Source: Journal of Alloys and Compounds - Category: Chemistry Source Type: research
Merck&Co. Inc., looking to strengthen its pipeline of cancer therapies, entered into a definitive agreement Tuesday to acquire Peloton Therapeutics in a deal that includes an upfront payment of $1.05 billion. Shareholders of Peloton will also be eligible to receive up to an additional $1.15 billion if regulatory and sales milestones are achieved for products the Dallas based company has in development. Peloton's lead new drug candidate is in late stage clinical testing as a potential treatment…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Publication date: July–August 2019Source: Reports of Practical Oncology &Radiotherapy, Volume 24, Issue 4Author(s): Marika Musielak, Igor Piotrowski, Wiktoria M. SuchorskaAbstractOver the past two decades nanotechnology has become an important part of novel medical research. Researchers have made great progress in developing nanotechnology applications used for detecting and treating oncological diseases. Recently, many research groups have focused on the use of superparamagnetic iron oxide nanoparticles (SPIONs) in cancer treatment. Due to the range of therapeutic properties and possibilities of various modifica...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Contributors : Mark A Dawson ; Charles C Bell ; Enid Y LamSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe prevailing model of therapeutic resistance in cancer posits that malignant cells acquire genetic mutations in the context of therapeutic pressure that negate the efficacy of the drug. This mutation centric view of therapeutic resistance has recently been challenged by emerging evidence that shows a paucity of genetic diversity in malignant cells that evade therapeutic challenge emphasizing the role of epigenetic evolution in drug resistance. We have previously established that...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Science